Mark Lowdell's most recent trade in INmune Bio Inc was a trade of 7,211 Common Stock done at an average price of $1.4 . Disclosure was reported to the exchange on July 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.40 per share. | 02 Jul 2026 | 7,211 | 1,518,017 (14%) | 0% | 1.4 | 10,095 | Common Stock |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | 02 Jul 2026 | 7,211 | 7,212 | - | - | Common Stock Purchase Warrant | ||
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 600,000 | 600,000 | - | - | Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2025 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Nov 2025 | 400,000 | 0 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2025 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Nov 2025 | 180,000 | 0 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2025 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Nov 2025 | 140,000 | 0 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2025 | 104,000 | 104,000 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Nov 2025 | 104,000 | 0 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2025 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Nov 2025 | 100,000 | 0 | - | - | Stock Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2024 | 140,000 | 140,000 | - | - | Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 100,000 | 100,000 | - | - | Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Apr 2024 | 14,423 | 14,423 | - | - | Common Stock Warrants (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 8.32 per share. | 19 Apr 2024 | 14,423 | 1,510,806 (14%) | 0% | 8.3 | 119,999 | Common Stock |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 104,000 | 104,000 | - | - | Option (right to buy) | |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 8.43 per share. | 21 Mar 2022 | 23,590 | 1,496,383 (13%) | 0% | 8.4 | 198,864 | Common Stock |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 03 Nov 2021 | 701 | 1,472,793 (13%) | 0% | 20 | 14,020 | Common Stock |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 27 Oct 2021 | 2,357 | 1,473,494 (13%) | 0% | 20 | 47,140 | Common Stock |
| INmune Bio Inc | Mark Lowdell | Chief Scientific Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 22 Oct 2021 | 400 | 1,475,851 (13%) | 0% | 20 | 8,000 | Common Stock |